Literature DB >> 18300802

Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.

Adeboye O Osunkoya1, Matthew E Nielsen, Jonathan I Epstein.   

Abstract

Mucinous adenocarcinoma of the prostate is one of the least common variants of prostate cancer. The prognosis of this variant of prostate cancer remains controversial. We present 47 cases (1991 to 2006) of mucinous carcinomas treated by radical prostatectomy. Mean patient age at diagnosis was 56 years (range: 44 to 69 y). The mean preoperative prostate-specific antigen (PSA) level was 9.0 ng/mL (range: 1.9 to 34.3 ng/mL). Clinical stages were T1c (34 cases), T2a (7 cases), and T2b (6 cases). The mean percentage of tumor composed of the mucinous component was 52% (range: 25% to 90%). The mean Gleason score was 7 with scores of 6 in 6 cases (12.8%), 7 in 37 cases (78.7%), and 8 in 4 cases (8.5%). Margins were positive in 4 cases of mucinous adenocarcinoma of the prostate. Only 2 cases had isolated margin positivity in the nonmucinous acinar component of cancer. In 12 cases (25.5%), mucinous adenocarcinoma had established extraprostatic extension (EEPE). Eight cases (17.0%) had isolated EEPE of nonmucinous cancer. The 1 lymph node metastasis contained nonmucinous cancer. All together, taking into account both the mucinous and nonmucinous tumor, 20/47 cases (42.5%) had EEPE and 6/47 (12.7%) had positive margins. The 1 lymph node metastasis contained nonmucinous cancer. The mean follow-up for those without progression was 5.6 years (median 6 y, range: 1 to 15 y). One patient (2.1%) progressed 3 years after his radical prostatectomy (5 y actuarial progression-free risk 97.2%). Using the Kattan nomogram, the predicted mean 5-year PSA progression-free risk for nonmucinous prostate cancer with the same PSA and postoperative findings as in the current study was 85.4%. This study confirms that mucinous adenocarcinoma of the prostate treated by radical prostatectomy is not more aggressive, and possibly even less aggressive than nonmucinous prostatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300802     DOI: 10.1097/PAS.0b013e3181589f72

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review.

Authors:  Lijie Zhang; Lihua Zhang; Ming Chen; Quan Fang
Journal:  Mol Clin Oncol       Date:  2018-07-30

Review 3.  Grading of Prostate Cancer: Past, Present, and Future.

Authors:  Andres Matoso; Jonathan I Epstein
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

4.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

5.  TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Authors:  Samson W Fine; Anuradha Gopalan; Margaret A Leversha; Hikmat A Al-Ahmadie; Satish K Tickoo; Qin Zhou; Jaya M Satagopan; Peter T Scardino; William L Gerald; Victor E Reuter
Journal:  Mod Pathol       Date:  2010-06-18       Impact factor: 7.842

6.  Collagenous micronodules in prostate cancer revisited: are they solely associated with Gleason pattern 3 adenocarcinomas?

Authors:  Mi J Kim; Mukul K Divatia; Jeong H Lee; Steven Shen; Brian J Miles; Jun H Hwang; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 7.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

8.  Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation.

Authors:  Christos Kalaitzis; Michael Koukourakis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; Efthimios Sivridis; Athanasios Bantis; Stavros Touloupidis
Journal:  Case Rep Urol       Date:  2014-01-29

9.  Radical exenteration surgery is curative in locally advance mucinous prostatic adenocarcinoma involving bladder and rectum.

Authors:  Vincent S W Koo; Naing N K Lynn; Mark F Saxby
Journal:  J Surg Case Rep       Date:  2010-06-01

10.  Case Report: Mucinous Adenocarcinoma Arising From Congenital Ejaculatory Duct Cyst.

Authors:  Hua Shen; Kai Liao; Weili Wu; Gongyu Li; Shijin Chen; Nan Nan; Hongbo Yu; Hongfei Wu
Journal:  Pathol Oncol Res       Date:  2021-03-26       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.